16-Nov-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. They are heavily reliant on our expertise with using the Freedom of Information Act. Probes Reporter is in the process of converting to a paid...
Disclosure Insight - Commentary & Analysis
12-Nov-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. They are heavily reliant on our expertise with using the Freedom of Information Act. Probes Reporter is in the process of converting to a paid...
23-Oct-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. Valeant Pharmaceuticals $VRX $116.16 Expect an array of protracted, distracting, and expensive investigations. As of 30-...
13-Oct-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. Soon Probes Reporter will become a paid subscription service. At that time you should expect both timing and access to our content that you enjoy...
7-Oct-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. Soon Probes Reporter will become a paid subscription service. At that time you should expect both timing and access to our content that you enjoy...
30-Sep-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. This report was sent out before the market opened today for free (with registration). Soon Probes Reporter will become a paid subscription...
29-Sep-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. Ventas, Inc. $VTR We don’t buy that we are getting the full story here. What’s missing could hurt the shares later. Facts of Interest or...
29-Sep-2015 - Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC. Rayonier, Inc. $RYN A disclosed SEC investigation is confirmed as on-going. Company says it’s not material. We disagree. It’s formal too....